secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-12-15T23:59:59+00:00
Accession:  0000950170-23-070574
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma dismisses Ernst & Young, engages KPMG as new auditor
------------------------------------------------------------------

- Board approved dismissal of E&Y as independent auditor on Dec 11, 2023; E&Y letter filed as Exhibit 16.1.
- KPMG engaged as new independent auditor for fiscal year ending Mar 31, 2024, effective same date.
- No disagreements or reportable events with E&Y during fiscal 2023 or subsequent interim period.
- Decision based on KPMG's US location, competitive review, and other business factors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023070574/0000950170-23-070574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023070574/acst-20231211.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-070574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer